The Trump administration has also pushed back against Covid vaccine recommendations, and the FDA toughened its requirements ...

In today’s Pharmaceutical Executive Daily, leadership turnover continues across key federal health agencies under the Trump ...

Agencies such as FDA, Centers for Disease Control (CDC), Health and Human Services (HHS), and The Center for Drug Evaluation ...

In today's Pharmaceutical Executive Daily, President Trump signs an executive order imposing 100% tariffs on imported ...

The U.S. pharmaceutical market is at a critical inflection point in early 2026. For decades, the industry has operated within a framework that, while fostering significant innovation, has also ...

In today's Pharmaceutical Executive Daily, the Trump administration delays its appeal of the federal ruling blocking RFK ...

When the bubble bursts, the tools that survive will not be the ones that generated the best demos. They will be the ones ...

Soley Therapeutics’ co-founder and CEO Yerem Yeghiazarians, MD, spoke with Pharmaceutical Executive about the unique approach ...

The deal continues Shionogi’s streak of acquisitions to begin 2026, as the company began the year acquiring $2.1 Billion ViiV ...

In today's Pharmaceutical Executive Daily, President Trump signs an executive order imposing 100% tariffs on imported patented pharmaceuticals under Section 232, with significant carve-outs for ...

Merck is partnering with Infinimmune in a deal worth up to $838 million to leverage AI-driven antibody discovery. Do you know ...

MFN policies are likely to impact more than pricing, and drug companies may alter drug launch plans in the future.